Breast Cancer Screening Test Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Breast Cancer Screening Test Market Expected To Become By 2029 Compared With Its 2025 Level?

The market encompassing screening tests for breast cancer has experienced considerable expansion in the recent past, projected to escalate from its 2024 valuation of $2.31 billion to $2.49 billion by 2025, reflecting a consistent annual growth rate (CAGR) of 7.9%. This upward trajectory witnessed during the historical timeframe is fundamentally driven by several key factors: the expansion of insurance coverage and reimbursement frameworks, a heightened emphasis placed on proactive health maintenance, greater individual awareness of personal well-being, augmented investment in investigation and development activities, and increased public knowledge regarding the benefits inherent in identifying conditions early.

Anticipation points toward considerable expansion within the breast cancer screening test sector over the subsequent years, culminating in a market valuation of $3.41 billion by 2029, propelled by an 8.2% compound annual growth rate. This upward trajectory through the projection timeframe is fundamentally driven by the rising occurrence of breast cancer cases globally, bolstered government support and programs, escalating outlays on healthcare, the broadening deployment of portable screening facilities, and the expanding demographics of the female populace. Key market movements shaping this era will involve progress in diagnostic imaging apparatus, the introduction of screening techniques that do not require invasive procedures, forward strides in genetic assessment capabilities, developments in genomic evaluation, alongside the maturation of screening services delivered via mobile platforms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24180&type=smp

Which Major Market Drivers Are Shaping The Future Of The Breast Cancer Screening Test Market?

Anticipated increases in breast cancer occurrences are projected to fuel the expansion of the market for breast cancer screening procedures in the near future. This malignancy involves the unrestrained proliferation of atypical cells within the mammary gland, capable of developing into a mass and possibly metastasizing to distant locations in the body. The escalation in breast cancer cases is largely attributed to the demographic shift towards an older worldwide population, given that increasing age constitutes a significant determinant for contracting the illness, and greater longevity leads to a larger pool of susceptible individuals. Screening examinations for breast cancer are vital as they allow for the early identification of the condition, thereby boosting the probability of effective therapeutic outcomes and diminishing fatalities associated with the disease. To illustrate, Breastcancer.org, an American non-profit entity, suggested in March 2025 that an estimated 316,950 women would receive an invasive breast cancer diagnosis during 2025, alongside the projection of 59,080 newly identified instances of non-invasive ductal carcinoma in situ (DCIS). Furthermore, as reported in December 2024 by the Public Health Agency of Canada, a governmental body in Canada, approximately 28,600 Canadian females were anticipated to be diagnosed with breast cancer in 2022, with an estimated 5,500 succumbing to the ailment. Consequently, the escalating frequency of breast cancer diagnoses serves as the primary impetus for the growth observed in the breast cancer screening test market.

How Is The Breast Cancer Screening Test Market Segmented?

The breast cancer screening testmarket covered in this report is segmented –

1) By Diagnostic Test Type: Blood Marker Test, Imaging Test, Genetic Test, Immunohistochemistry Test

2) By Risk Level: High-risk Population, Moderate-risk Population, Average-risk Population

3) By End User: Hospitals, Diagnostic Centres, Cancer Institutes, Research Laboratories

Subsegments:

1) By Blood Marker Test: Circulating Tumor Cells (Ctcs) Test, Gene Expression Profiling Test, Circulating Tumor Dna (Ctdna) Test, Proteomic Biomarker Test

2) By Imaging Test: Mammography, Magnetic Resonance Imaging Screening Test, Molecular Breast Imaging Test, Positron Emission Tomograph Scan, Ultrasound

3) By Genetic Test: Fluorescence In Situ Hybridization, Her Gene Test

4) By Immunohistochemistry (Ihc) Test: Estrogen Receptor (Er) Test, Ki-67 Proliferation Marker Test, Progesterone Receptor (Pr) Test, Her2 Or Neu Test

What Are The Latest Industry Trends Transforming The Breast Cancer Screening Test Market?

Leading firms within the breast cancer detection market are concentrating efforts on pioneering novel solutions, including mobile examination facilities, aiming to bolster ease of access, elevate the frequency of early identification, and broaden the reach of screening programs into regions lacking adequate service or geographically isolated locales. Such a mobile breast cancer screening apparatus constitutes a movable center outfitted with diagnostic imaging apparatus, like mammography tools, engineered to deliver breast cancer evaluations directly at the location within distant or underserved territories. To illustrate, in the ninth month of 2024, Granules India Ltd., an enterprise situated in India engaged in pharmaceutical production, introduced the Breast Health Express, a measure intended to intensify breast cancer screening efforts among economically disadvantaged populations. This mobile setup boasts contemporary mammography and ultrasound capabilities, facilitating superior quality assessments while in transit, and its primary objective is to serve remote and rural populations where healthcare infrastructure might be scant, consequently guaranteeing that females residing in isolated settings can avail themselves of crucial early detection diagnostics.

Who Are The Key Multinational Companies Dominating The Breast Cancer Screening Test Market?

Major companies operating in the breast cancer screening test market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Fujifilm Corporation, Koninklijke Philips NV, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Hologic Inc., Hitachi High-Tech Corporation, Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Provista Diagnostics Inc., POC Medical Systems Inc., Niramai Health Analytix Pvt. Ltd., Kheiron Medical Technologies Limited, UE LifeSciences Inc., Dxcover Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/breast-cancer-screening-test-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Breast Cancer Screening Test Market?

North America was the largest region in the breast cancer screening test market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer screening test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Breast Cancer Screening Test Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24180&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Screening Test Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Imaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-imaging-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795